Zydus wordmark
Zydus Pharmaceuticals is providing refunds for 340B overcharges during 2022 on 83 NDCs.

Zydus Pharmaceuticals USA Announces Refunds for 340B Overcharges During 2022

Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax, hyperactivity drug Adderall, hypertension drug Cardizem, and enlarged prostrate and erectile dysfunction treatment Cialis.

The refund notice is dated Feb. 14. The U.S. Health Resources and Services Administration posted it on the Office of Pharmacy Affairs website March 3. It lists 83 Zydus generic drugs spanning a wide range of indications.

Zydus USA, based in Pennington, N.J., said its recalculated 340B ceiling prices resulted from revised pricing data submitted to the Centers for Medicare & Medicaid Services from July 1, 2021, through March 31, 2022. It said 340B covered entities owed an aggregated refund across applicable NDCs for $25 or more will be contacted directly by, or on behalf of Zydus with information on how their refunds will be processed. Those entities owed a refund of less than $25 are being offered their refunds via the posted notice, it said.

Zydus’ notice includes contact information for 340B covered entities that believe they are entitled to a refund on the applicable NDCs, but did not receive a communication from or on behalf of Zydus.

Contributor | + posts